NLS Pharmaceutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018
Cash & Equivalents	8.95	5.43	0.09	0.22	0.01
Cash & Cash Equivalents	8.95	5.43	0.09	0.22	0.01
Cash Growth	64.76%	5695.69%	-57.46%	3198.40%	-
Other Current Assets	0.3	0.29	0.1	0.16	0.08
Total Current Assets	9.25	5.72	0.2	0.38	0.09
Property, Plant & Equipment	0.02	0.03	0	0	0
Other Long-Term Assets	0.01	0.01	1.01	0.31	0.06
Total Long-Term Assets	0.03	0.04	1.01	0.31	0.06
Total Assets	9.28	5.76	1.21	0.7	0.15
Accounts Payable	2.37	1.74	4.01	2.51	1.13
Deferred Revenue	2.5	2.5	2.5	2.5	0
Current Debt	0	0	1.77	0.69	0.71
Other Current Liabilities	-1.51	-1.83	-1.07	-1.66	0.58
Total Current Liabilities	3.36	2.4	7.2	4.04	2.41
Long-Term Debt	0	0	0.31	0.15	6.39
Other Long-Term Liabilities	2.64	2.82	2.68	2.68	0.16
Total Long-Term Liabilities	2.64	2.82	2.99	2.83	6.54
Total Liabilities	6	5.22	10.2	6.87	8.96
Total Debt	0	0	2.08	0.84	7.09
Debt Growth	-	-	147.56%	-88.13%	-
Retained Earnings	-58.2	-41.71	-29.76	-26.9	-21.45
Comprehensive Income	-0.05	-0.15	-0.02	-0.02	-0.01
Shareholders' Equity	3.28	0.54	-8.98	-6.17	-8.81
Net Cash / Debt	8.95	5.43	-1.99	-0.62	-7.09
Net Cash / Debt Growth	64.76%	-	-	-	-
Net Cash Per Share	0.45	0.46	-0.29	-0.09	-1.14
Working Capital	5.89	3.32	-7.01	-3.65	-2.32
Book Value Per Share	0.17	0.05	-1.29	-0.90	-1.41

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).